Zydus to Pay Astellas $120 Million to End Myrbetriq Patent Fight

Zydus Lifesciences Ltd. said it will pay Astellas Pharma Inc. $120 million to settle a lawsuit over its generic Myrbetriq tablets a day after their jury trial finished, ending a consolidated case in which Zydus was the last remaining generic-drug maker.

Zydus conceded that its 25- and 50-milligram extended-release tablets of generic mirabegron, Myrbetriq’s active ingredient, infringe US Patent Nos. 10,842,780, 11,707,451, 12,059,409 and 12,097,189—and that the patents are valid and enforceable—according to a proposed consent judgment filed Thursday in the US District Court for the District of Delaware.

Zydus said Thursday in a stock-exchange disclosure that, ...